Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Professor of Rheumatology, University of Oxford

Do you feel we have moved into the era of top-down therapy for patients with multi-organ IgG4-RD or should steroids remain as first line therapy? Should this be modelled on treatment of vasculitis?